• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Omadacycline is noninferior to moxifloxacin in treating community acquired bacterial pneumonia

byShani ChibberandDayton McMillan
February 11, 2019
in Chronic Disease, Infectious Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Intensive care unit (ICU) hospitalized adults with community acquired bacterial pneumonia had comparable clinical responses when taking antibiotic courses of omadacycline, a new trial antibiotic, versus moxifloxacin.

2. The observed safety profile of omadacycline was noted to be consistent with other known tetracyclines.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Community acquired pneumonia is a common cause of hospitalization; it also has increasing rates of resistance to traditional antibiotics necessitating research for new antibiotic agents. Omadacycline is a new antibiotic from the tetracycline class, and it has in vitro activity against known pathogens commonly implicated in community acquired bacterial pneumonia. In this current study, researchers assessed the efficacy and safety profile of omadacycline versus a traditional antibiotic, moxifloxacin, among adult ICU patients with community acquired pneumonia. Overall, omadacycline was noninferior to moxifloxacin when early clinical response and overall clinical response rates were assessed, based on patient survival and symptoms. Researchers also noted that the safety profile of omadacycline was comparable to other tetracyclines.

Though results may not be generalizable to a larger patient population, this study still highlights that clinicians may be able to consider newer antibiotic agents to treat resistant bacterial community acquired pneumonia. A notable strength includes thorough microbial assessment which determined the causative pathogen in 50% of cases. This may also present a limitation as real world rates of pathogen identification are dramatically lower.

Click to read the study in NEJM

Relevant Reading: New antibiotics for community-acquired pneumonia

RELATED REPORTS

Lower dose and shorter duration of amoxicillin treatment noninferior to higher dose and longer treatment in children with community-acquired pneumonia

#VisualAbstract: Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

In-Depth [randomized controlled trial]: This multicenter, phase III, double-blind, noninferiority randomized control trial enrolled 774 participants across 86 sites between 2015 to 2017. Patients were randomized in a 1:1 ratio to either receive 7 to 14 days of 100 mg omadacycline or 400 mg moxifloxacin (both initially administered intravenously with option to switch to oral formulation after 3 days). The primary outcome of this study was evidence of an early clinical response, assessed between 72 to 120 hours after the initial dose of antibiotics were given. Investigators assessed for symptoms of community acquired pneumonia (cough, sputum production, pleuritic chest pain, dyspnea) and measured if there was improvement in symptoms to determine if there was adequate early clinical response. Secondary endpoints included investigator-assessed clinical response at the post-treatment evaluation period (5 to 10 days after the last dose of antibiotic was given) and evidence of adverse events. Results showed that the most frequently encountered identified pathogens that caused community acquired bacterial pneumonia were Mycoplasma pneumoniae (33%). Streptococcus pneunomiae (20%), Legionella pneumophila (19%), Chlamydia pneumoniae (15%) and Haemophilus influenza (12%). Omadacycline was shown to be noninferior to moxifloxacin when early clinical response rates were measured among an intention-to-treat population (81.1% vs 82.7% respectively; -1.6 percentage difference; 95% confidence interval [CI], -7.1 to 3.8). Clinical response rates were also similar when assessed at the end of the treatment course (87.6% vs 85.1%; 2.5 percentage difference; 95% CI, -2.4 to 7.4). Adverse events occurred in 41.1% of patients in the omadacycline group and 48.5% of patients in the moxifloxacin group. The most common adverse events included gastrointestinal events, such as constipation vomiting and nausea. Severe adverse events occurred in 6.0% of omadacycline patients and in 6.7% of moxifloxacin patients, including twelve total deaths (8 in omadacycline group and 4 in the moxifloxacin group).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: community acquired pneumoniaomadacycline
Previous Post

RNA interference agent givosiran appears safe in phase I trial

Next Post

2 Minute Medicine Rewind February 11, 2019

RelatedReports

X-ray after foreign body removal by esophagoscopy is not cost effective
Emergency

Lower dose and shorter duration of amoxicillin treatment noninferior to higher dose and longer treatment in children with community-acquired pneumonia

November 3, 2021
#VisualAbstract: Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia
StudyGraphics

#VisualAbstract: Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

October 28, 2021
Prescription of antibiotics for acute respiratory infections increasing
Emergency

Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

October 21, 2021
Prescription of antibiotics for acute respiratory infections increasing
Pulmonology

3 days of β-lactam therapy is non-inferior to 8 days of therapy among patients with community-acquired pneumonia

June 25, 2021
Next Post
2 Minute Medicine Rewind February 11, 2019

2 Minute Medicine Rewind February 11, 2019

The PIONEER-HF Trial: Sacubitril-valsartan linked to superior outcomes in acute decompensated heart failure

The PIONEER-HF Trial: Sacubitril-valsartan linked to superior outcomes in acute decompensated heart failure

Long-term Acetaminophen Use in Pregnancy and ADHD

Paracetamol plus ibuprofen significantly reduces post-operative morphine use in total hip arthroplasty patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.